



## ASX Announcement

### Monash IVF Group Limited (ASX: MVF)

16 November 2017

#### APPENDIX 3Y NOTICE

---

An Appendix 3Y by MVF (**Monash IVF**) for James Thiedeman, former CEO of Monash IVF, is attached.

Monash IVF advises that:

1. the delay in lodgement of the Appendix 3Y Notice was due to an internal administrative oversight. Upon being identified by Monash IVF, the notice has been immediately lodged.
2. Monash IVF and its directors are aware of their obligations under ASX Listing Rule 3.19A. Each director is made aware of this obligation pursuant to their terms of appointment. In addition, Monash IVF's Securities Trading Policy includes the requirement that all directors must notify the Company Secretary of any dealings in Monash IVF's securities within 2 business days of such dealing occurring.
3. Monash IVF's existing arrangements are considered adequate and the late lodgement of this particular Appendix 3Y notice was an isolated incident. Monash IVF is mindful of its disclosure obligations under ASX Listing Rule 3.19A.2. The directors are also aware of their personal obligation involving Monash IVF's securities.

**Michael Knaap**  
**Chief Financial Officer & Company Secretary**  
**Monash IVF Group Limited**  
**Tel: +61 (0) 3 9420 8235**

#### **About Monash IVF Group**

Monash IVF Group is a leading provider of assisted reproductive services and specialist womens imaging and diagnostic services in Australia and Malaysia. The Group is a driving force in the development of assisted reproductive technologies and has many Australian and world firsts since the work of our pioneers who achieved the first IVF pregnancy in the world in 1973.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Monash IVF Group Limited
<b>ABN</b> 90 169 302 309

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Note that this appendix 3Y notice updates the Appendix 3Y notice lodged on 11 August 2014 and now includes Part 3

<b>Name of Director</b>	Benjamin James Thiedeman
<b>Date of last notice</b>	22 September 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	04/10/2017
<b>No. of securities held prior to change</b>	850,758 Ordinary Shares 800,000 Options
<b>Class</b>	Ordinary Shares and Options
<b>Number acquired</b>	Nil
<b>Number disposed</b>	660,000 Options lapsed
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	n/a
<b>No. of securities held after change</b>	850,758 Ordinary Shares 140,000 Options

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Monash IVF Group Limited ("MVF") announces the vesting of 140,000 unlisted options issued under MVF's Long Term Incentive Plan ("Plan") held by Mr James Thiedeman.</p> <p>Following testing of the earning per share growth hurdle in accordance with the terms of the Plan, MVF has determined that 140,000 unlisted Tranche 1 options issued under the Plan ("Options") have vested and are exercisable and that 260,000 Tranche 1 Options have lapsed.</p> <p>Following testing of the total shareholder return hurdle in accordance with the terms of the Plan, MVF has determined that 400,000 Tranche 2 Options have lapsed. As Mr Thiedeman became a Leaver under the Plan on 10 November 2017, the 140,000 Tranche 1 Options may be exercised in accordance with the terms of the Plan at any time prior to 5.00pm 8 December 2017 - 28 days after the date he became a Leaver.</p> <p>This notice is given for the purposes of ASX Listing Rule 3.10.7</p>
---	---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	n/a
<b>Interest acquired</b>	n/a

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	n/a
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---

+ See chapter 19 for defined terms.